Please ensure Javascript is enabled for purposes of website accessibility

Why Zafgen Stock Is Crashing Today

By Keith Speights - Nov 26, 2018 at 11:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News of an FDA clinical hold zaps Zafgen's share price.

What happened

Zafgen (ZFGN) stock crashed on Monday, with shares plunging 41.9% as of 11:12 a.m. EST. This huge drop came after the clinical-stage biotech announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on the Investigational New Drug Application (IND) for experimental type 2 diabetes drug ZGN-1061.

The FDA's decision to place a clinical hold on any clinical testing of ZGN-1061 stemmed from concerns about the potential for cardiovascular safety risk "based on the company's prior compound." This referenced Zafgen's previous obesity drug, beloranib, which the company abandoned after patients died in late-stage studies. Both beloranib and ZGN-1061 are MetAP2 inhibitors.

Man holding hand up to signal "stop."

Image source: Getty Images.

So what

An FDA clinical hold doesn't necessarily mean the end of the road for a drug. Zafgen could address the agency's concerns and advance ZGN-1061 to clinical testing. However, it definitely means a delay -- and potentially a lengthy one.

Any delay for a clinical-stage biotech hurts. It especially hurts when the delay is for the biotech's lead pipeline candidate. That's the situation for Zafgen.

ZGN-1061 is already in a phase 2 clinical study, but that study is being conducted outside of the U.S. The FDA's clinical hold has no impact on the study. However, to achieve the kind of success that investors hope for, Zafgen has to launch a drug in the U.S. Any hopes of such a launch now have to be placed on pause.

Despite the big setback announced today, there was a sliver of good news. Zafgen now expects that its cash stockpile will fund operations through 2020 as a result of the delay in clinical testing of ZGN-1061.

Now what

Zafgen's next step is to request a meeting with the FDA to discuss the clinical hold and possible alternatives for addressing the safety concerns about ZGN-1061. The biotech stated that the FDA's clinical hold letter "outlined multiple potential paths for moving forward, including nonclinical or clinical options, to address these concerns."

The company also expects to report top-line data from the 1.8 mg dose cohort of its ex-U.S. phase 2 clinical study of ZGN-1061 early next year. Zafgen reported positive results earlier this year for the initial cohort of this study, which included a range of doses up to 0.9 mg.

In the meantime, Zafgen's shares are likely to remain highly volatile. Investors are probably better off watching the developments for this clinical-stage biotech from the sidelines.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zafgen, Inc. Stock Quote
Zafgen, Inc.
ZFGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.